International Journal of Hematology

Papers
(The H4-Index of International Journal of Hematology is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
COVID-19-associated coagulopathy and disseminated intravascular coagulation245
Changes of hematological and immunological parameters in COVID-19 patients90
Recent advances in the research and management of sepsis-associated DIC45
Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine37
Engineering the next generation of CAR-NK immunotherapies36
The human spleen as the center of the blood defense system35
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia30
Multiple myeloma with high-risk cytogenetics and its treatment approach29
Severe immune thrombocytopenic purpura in critical COVID-1925
Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera24
Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies22
Comparison of clinical phenotype with genetic and laboratory results in 31 patients with congenital dysfibrinogenemia in northern Slovakia22
New-onset Evans syndrome associated with systemic lupus erythematosus after BNT162b2 mRNA COVID-19 vaccination22
Immune thrombocytopenia in a patient with COVID-1921
JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN)21
Characterization of hereditary red blood cell membranopathies using combined targeted next-generation sequencing and osmotic gradient ektacytometry20
A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X19
Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retr18
Clinical outcomes of persistent colonization with multidrug-resistant Gram-negative rods in adult patients undergoing single cord blood transplantation18
Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment18
Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan18
Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical 18
0.064062118530273